EGFR and cancer prognosis

Nicholson, Robert Ian, Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015 and Harper, Maureen Elaine 2001. EGFR and cancer prognosis. European Journal of Cancer 37 (S4) , pp. 9-15. 10.1016/S0959-8049(01)00231-3

Full text not available from this repository.

Abstract

Elevated levels of the epidermal growth factor receptor (EGFR), a growth-factor-receptor tyrosine kinase, and/or its cognate ligands have been identified as a common component of multiple cancer types and appear to promote solid tumour growth. This article examines the relationship between EGFR expression and cancer prognosis based on literature compiled on PubMed between 1985 and September 2000. More than 200 studies were identified that analysed relapse-free-interval or survival data directly in relation to EGFR levels in over 20 000 patients. Analysis of the data showed that 10 cancer types both express elevated levels of EGFR relative to normal tissues and have been studied in sufficient depth to allow sound judgements to be made concerning the association between EGFR and patient outlook. The EGFR was found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers. In these cancers, increased EGFR expression was associated with reduced recurrence-free or overall survival rates in 70% (52/74) of studies. In gastric, breast, endometrial and colorectal cancers, the EGFR provided more modest prognostic information, correlating to poor survival rates in 52% (13/25) of studies, while in non-small cell lung cancer (NSCLC), EGFR expression only rarely (3/10 studies) related to patient outlook. However, it is likely that the true prognostic significance of the EGFR has been underestimated as the published studies only assessed total cellular EGFR levels, rather than the activated form of the receptor, and were not standardised with regard to patient populations or assay methods. Finally, it is important to stress that failure to detect a prognostic significance for EGFR in any one cancer type does not necessarily preclude patients from benefiting from anti-EGFR therapies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	Neoplasms; Prognosis; Receptor; Epidermal growth factor; Receptor; ErbB-2
Publisher:	Elsevier
ISSN:	0014-2964
Last Modified:	18 Oct 2022 14:18
URI:	https://orca.cardiff.ac.uk/id/eprint/17101

Citation Data

Cited 1693 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item